Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on...
Hlavní autoři: | Watson, C, Bradley, J, Friend, P, Firth, J, Taylor, C, Bradley, JR, Smith, K, Thiru, S, Jamieson, N, Hale, G, Waldmann, H, Calne, R |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
2005
|
Podobné jednotky
-
Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
Autor: Watson, C, a další
Vydáno: (2004) -
Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.
Autor: Calne, R, a další
Vydáno: (1999) -
Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
Autor: Clatworthy, MR, a další
Vydáno: (2009) -
CAMPATH-1 FOLLOWING RENAL-TRANSPLANTATION - A RANDOMIZED TRIAL
Autor: Friend, P, a další
Vydáno: (1988) -
Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
Autor: Friend, P, a další
Vydáno: (1991)